Annual report pursuant to Section 13 and 15(d)

Related Party Transactions

v3.23.1
Related Party Transactions
12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

 

11. Related Party Transactions

 

In January 2022, we entered into an agreement with JT Pharma, a company for which James R. McNab, Jr., a member of our Board, serves as chief executive officer, to clarify certain provisions of the JT Agreement, pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved, made a payment of $100,000 and issued 51,021 shares of our common stock to JT Pharma.

 

During the year ended December 31, 2022, we made payments related to legal fees of approximately $75,000 to a law firm operated by one of our Board members.